Market accessCompany release

Glaukos third-quarter revenue rises 58% to $211.0m as iDose TR and Epioxa drive growth

🇺🇸 GLAUKOS Corp (GKOS) · Wed 28 Oct 2026

The ophthalmic company lifted its 2026 revenue guidance to $775–785 million and gave preliminary 2027 guidance of $1 billion, citing strong uptake of two recently launched products.

Glaukos reported record third-quarter revenue of $211.0 million on 28 October 2026, a 58% increase on the same period a year earlier. The company attributed the growth to two products: iDose TR for glaucoma and Epioxa for keratoconus.

US sales of iDose TR, the company's glaucoma therapy, were approximately $76 million in the quarter. Epioxa, an FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, generated roughly $53 million in net sales.

Glaukos raised its full-year 2026 revenue guidance to $775–785 million. It also issued preliminary 2027 guidance of $1 billion.

On market access, the company said payer access pathways now cover about 90% of commercial lives for Epioxa. J-code J2789 took effect on 1 July 2026. A J-code is a billing code within the US HCPCS system, used to identify drugs for reimbursement claims.

What it means for your team

  • Market-access teams may note that Glaukos reports payer pathways covering about 90% of commercial lives for Epioxa within its first full period of commercial sales.
  • The J-code J2789, effective 1 July 2026, gives Epioxa a dedicated billing identifier, which is relevant to claims processing and reimbursement planning.
  • The figures are company-reported; the summary provides no further detail on how the payer pathways are structured or on pricing.

Company's press release (SEC filing): GLAUKOS Corp ↗

Article written by VigiEye from the official source (GLAUKOS Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →